Literature DB >> 15210312

Competition and natural selection in a mathematical model of cancer.

John D Nagy1.   

Abstract

A malignant tumor is a dynamic amalgamation of various cell phenotypes, both cancerous (parenchyma) and healthy (stroma). These diverse cells compete over resources as well as cooperate to maintain tumor viability. Therefore, tumors are both an ecological community and an integrated tissue. An understanding of how natural selection operates in this unique ecological context should expose unappreciated vulnerabilities shared by all cancers. In this study I address natural selection's role in tumor evolution by developing and exploring a mathematical model of a heterogenous primary neoplasm. The model is a system of nonlinear ordinary differential equations tracking the mass of up to two different parenchyma cell types, the mass of vascular endothelial cells from which new tumor blood vessels are built and the total length of tumor microvessels. Results predict the possibility of a hypertumor-a focus of aggressively reproducing parenchyma cells that invade and destroy part or all of the tumor, perhaps before it becomes a clinical entity. If this phenomenon occurs, then we should see examples of tumors that develop an aggressive histology but are paradoxically prone to extinction. Neuroblastoma, a common childhood cancer, may sometimes fit this pattern. In addition, this model suggests that parenchyma cell diversity can be maintained by a tissue-like integration of cells specialized to provide different services.

Entities:  

Mesh:

Year:  2004        PMID: 15210312     DOI: 10.1016/j.bulm.2003.10.001

Source DB:  PubMed          Journal:  Bull Math Biol        ISSN: 0092-8240            Impact factor:   1.758


  21 in total

1.  First principles of Hamiltonian medicine.

Authors:  Bernard Crespi; Kevin Foster; Francisco Úbeda
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-03-31       Impact factor: 6.237

Review 2.  Clonal cooperativity in heterogenous cancers.

Authors:  Hengbo Zhou; Deepika Neelakantan; Heide L Ford
Journal:  Semin Cell Dev Biol       Date:  2016-08-28       Impact factor: 7.727

3.  Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution.

Authors:  Asier Erramuzpe; Jesús M Cortés; José I López
Journal:  Virchows Arch       Date:  2017-08-25       Impact factor: 4.064

4.  Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.

Authors:  David W Nauen; Andrew Guajardo; Lisa Haley; Kerry Powell; Peter C Burger; Christopher D Gocke
Journal:  Converg Sci Phys Oncol       Date:  2015-06-16

Review 5.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

6.  The origins and implications of intratumor heterogeneity.

Authors:  Franziska Michor; Kornelia Polyak
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-19

7.  The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.

Authors:  Steffen E Eikenberry; John D Nagy; Yang Kuang
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

Review 8.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

Review 9.  Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.

Authors:  José I López; Javier C Angulo
Journal:  Curr Urol Rep       Date:  2018-01-27       Impact factor: 3.092

Review 10.  What Animal Cancers teach us about Human Biology.

Authors:  Patricia Kattner; Katharina Zeiler; Verena J Herbener; Katia La Ferla-Brühl; Rebecca Kassubek; Michael Grunert; Timo Burster; Oliver Brühl; Anna Sarah Weber; Hannah Strobel; Georg Karpel-Massler; Sibylle Ott; Alexa Hagedorn; Daniel Tews; Ansgar Schulz; Vikas Prasad; Markus D Siegelin; Lisa Nonnenmacher; Pamela Fischer-Posovszky; Marc-Eric Halatsch; Klaus-Michael Debatin; Mike-Andrew Westhoff
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.